Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...

For Eisai and Biogen, the CHMP’s decision to stick by its previous call now punts the final approval verdict for Leqembi back to the European Commission (EC), which is the ultimate authority on ...

Eisai has filed for approval of its Alzheimer’s disease therapy Leqembi in South Korea ... that seem to be more common in patients with ApoE ε4 mutations and among those taking anticoagulants ...

The EMA’s Committee for Medicinal products for Human Use (CHMP) is standing by its opinion on Leqembi (lecanemab) after the European .mission pushed back against a recommendation in November 2024 that ...

NEW YORK – The European Commission will resume its review of Eisai and Biogen's marketing authorization application for their anti-amyloid Alzheimer's disease drug Leqembi (lecanemab), the companies ...

Specifically, your doctor will monitor your scans for amyloid-related imaging abnormalities (ARIA). This is because Leqembi treatment can cause ARIA. In fact, Leqembi has a boxed warning about the ...

In 2020, Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Four years later, she and her husband, Ken, halted the treatment.

In 2020, Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Four years later, she and her husband, Ken, halted the treatment. Sue's ...